



**Minutes of the Lancashire Medicines Management Group Meeting
Held on Thursday 10th October 2013 at Preston Business Centre**

PRESENT

Dr Tony Naughton (TN)	LMMG Chair	Lancashire CCG Network
Louise Winstanley (LW)	CCG Lead Pharmacist	NHS Fylde and Wyre CCG
Melanie Preston (MP)	Assistant Director Medicines Optimisation	NHS Blackpool CCG
Dr Pervez Muzzafar (PM)	GP Prescribing Lead	NHS Blackburn w/ Darwen CCG
Dr Kamlesh Sidhu (KS)	GP Prescribing Lead	NHS Lancashire North CCG
Alastair Gibson (AG)	Chief Pharmacist	Blackpool Teaching Hospitals
Lisa Rogan (LR)	Head of Medicines Commissioning	East Lancs & BwD CCGs
Pauline Bourne(PB)	Senior Pharmacist	University Hospitals of Morecambe Bay
Julie Landale (JLan)	Head of Medicines Optimisation	NHS Chorley & South Ribble and Greater Preston CCGs
Dr Sigrun Baier (SB)	GP Director	Chorley and South Ribble CCG
Gareth Price (GP)	Head Pharmacist	Lancashire Teaching Hospital Trust
Christine Woffindin (CW)	Pharmacist	East Lancashire Hospital Trust

IN ATTENDANCE

Linda Riley (observing)	Director of Delivery	NHS Staffs and Lancs CSU
Elaine Johnstone (EJ)	Senior Executive – Medicines Management	NHS Staffs and Lancs CSU
Brent Horrell (BH)	Head of Medicines Commissioning	NHS Staffs and Lancs CSU
Julie Lonsdale (JLon)	Head of Medicines Performance	NHS Staffs and Lancs CSU
Warren Linley (WL)	Senior Commissioning Pharmacist	NHS Staffs and Lancs CSU
Dr Venu Duddu (VD)	Consultant Psychiatrist	Lancashire Care NHS Trust

ITEM	<u>SUMMARY OF DISCUSSION</u>	ACTION
2013/128	<p><u>WELCOME & APOLOGIES FOR ABSENCE</u> The Chair welcomed everyone to the meeting and introduced Linda Riley, Director of Delivery Staffs and Lancs CSU.</p> <p>Linda Riley thanked the LMMG for their welcome, offered continued support and mentioned that other CSU areas are looking at the LMMG model.</p> <p>Apologies for absence were noted on behalf of Sonia Ramdour, Dr David Shakespeare, Eric Bonsell, Sakthi Karunanithi</p>	
2013/129	<p><u>DECLARATIONS OF INTEREST PERTINENT TO AGENDA</u> None</p>	
2013/130	<p><u>DECLARATION OF ANY OTHER URGENT BUSINESS</u> None</p>	
2013/131	<p><u>MINUTES OF THE LAST MEETING –12th September 2013</u> The minutes of the meeting held on 12thSeptember 2013 were agreed as an accurate record.</p> <p><u>2013/117 Tapentadol SR – Item outstanding from last agenda for action</u></p> <p><u>Action:</u> BH informed LMMG that a letter had been drafted but not yet sent to pain consultants. It was agreed that it would be useful to include the East Lancashire pain guidelines as an example.</p>	BH
2013/132	<p><u>MATTERS ARISING (not on the agenda)</u> None</p>	
2013/140 (agenda item order change)	<p><u>ADHD SHARED CARE DOCUMENT</u> (agenda item brought forward)</p> <p>Julie Lonsdale presented the paper. LMMG was asked to look at the content and ensure this was clinically appropriate and acceptable to the committee. Amendments which had been made to the shared care document following comments during the consultation phase were highlighted in blue text</p> <p>LMMG agreed to the clinical content of the shared care following the amendments below</p> <ul style="list-style-type: none"> • remove the contact details and patient ID label section from the front page • removal of contact details information, to be replaced with a section for the service to complete at the point of forwarding the document to each patient's GP <p><u>Action:</u> TN to raise with the CAG the mechanism for the co-ordinated implementation of shared care across primary care. To develop an information sheet to support GP's with the routine assessment required</p>	<p>TN liaise with CAG</p> <p>JLon to liaise with Sonia Ramdour to develop an information sheet</p>

	<u>NEW MEDICINES RECOMMENDATIONS</u>	
2013/133	<p><u>Ticagrelor</u></p> <p>WL talked through the new medicines evidence review for Ticagrelor (Brilique®) for acute coronary syndromes.</p> <p>It was noted that the evidence for ticagrelor versus other antiplatelets has not changed since the NICE Technology Appraisal 236 was issued in 2011. WL highlighted that NICE has recently clarified the meaning of its guidance when treatments are recommended as “treatment options” and that this means that commissioning policies should not preclude a NICE recommended treatment option.</p> <p>Following discussion, LMMG accepted the draft recommendation that ticagrelor should be recommended for use in ACS in line with NICE TA 236.</p> <p><u>RAG status recommended AMBER 0.</u></p> <p><u>Action:</u> LMMG members requested the following before taking this recommendation back to CCGs:</p> <ul style="list-style-type: none"> • An agreed treatment protocol / algorithm from the cardiac network to outline the patients and clinical circumstances in which ticagrelor should and should not be used in ACS. 	WL to contact the cardiac network
2013/134	<p><u>Lisdexamfetamine</u></p> <p>BH talked through the new medicines recommendation paper for Lisdexamfetamine (Elvanse®) for ADHD in children and young adults.</p> <p><u>Following discussion LMMG recommended:</u></p> <p>Option 1: Lisdexamfetamine (Elvanse®) is not recommended for use in the treatment of ADHD in children and young adults</p> <p><u>RAG status BLACK</u></p>	BH to update the recommendation and upload to the website
2013/135	<p><u>Medicines Horizon Scanning Paper Quarter 3 2013/14</u> (This item was deferred from the 12th September LMMG)</p> <p>BH talked through the paper - quarter 3 2013/14</p> <ul style="list-style-type: none"> • LMMG noted that the combination inhaler did not meet the criteria for review however due to the clinical condition being treated and that combination products were standard practice it was agreed to add Ultibro onto the work plan <p><u>Action:</u> BH to add Ultibro® (glycopyrronium bromide / Indacaterol) inhaler to the work plan</p>	BH
2013/136	<p><u>LMMG New Medicine Review Work Plan (update</u></p> <p>BH and JLon talked to the work plan update.</p> <p><u>New Medicines Reviews</u></p> <ul style="list-style-type: none"> • LMMG agreed to remove Lomitapide from the work plan as NHS England was the responsible commissioner. 	

	<ul style="list-style-type: none"> LMMG felt that it was appropriate to put the Tocilizumab and Abatacept Monotherapy requests on hold until the Rheumatology Pathway had been considered by CCGs. LMMG agreed to remove abliglutide from the work plan for the time being given that its launch has been delayed until Q2 2014/15 and the FDA have asked for an extra 3 months to consider the information submitted. <p><u>Prescribing Guidelines</u></p> <ul style="list-style-type: none"> LMMG agreed that the highest priority guidelines to be reviewed were the COPD and Diabetes guidelines BH informed LMMG that the COPD guidance was in the process of being drafted; the committee requested that the list of clinicians currently held for the reference group is circulated to members for review prior to the draft document being circulated. LMMG asked that asthma and pain guidance are added to the work plan The policy for prescribing of vitamins and minerals was discussed and it was agreed that this would be reviewed to ensure that it is fit for purpose. JLon informed LMMG that the latest version of the NEWT guidance was still awaited to start work on the Specials alternative document. LMMG agreed that this piece of work would be considered a lower priority to COPD and Diabetes guidelines. 	BH to circulate list of clinicians for the COPD guidance reference group
	<u>NATIONAL DECISIONS FOR IMPLEMENTATION</u>	
2013/137	<p><u>NICE Technology Appraisal Guidance for medicines published in July, August - Sept 2013</u></p> <p>EJ presented the paper and LMMG was asked to note the list of NICE TAGs published in July - September 2013 and consider the proposed traffic light recommendations for the relevant medicines.</p> <p><u>LMMG recommended</u></p> <ul style="list-style-type: none"> TAG 292 Bipolar disorder (adolescents) - aripiprazole - RED TAG 293 Thrombocytopenic purpura – eltrombopag - RED TAG 294 Macular Degeneration (wet age-related) – Aflibercept (1st line) - RED TAG 276 Cystic fibrosis (pseudomonas lung infection) – colistimethate sodium and tobramycin - RED TAG 295 Everolimus in combination with exemestane for treating advanced HER-2- negative-hormone-receptor-positive breast cancer after endocrine therapy - BLACK TAG 296 Lung cancer (non-small-cell anaplastic lymphoma kinase fusion gene, previously treated) – crizotinib - BLACK 	
2013/138	<p><u>NHS England Policies relating to Medicines – September 2013</u></p> <p>BH talked through the paper; LMMG is asked to consider the prescribing policies listed that have been developed by NHS England, and to agree the RAG status for inclusion on the LMMG website.</p> <p><u>LMMG recommended</u></p> <ul style="list-style-type: none"> Eculizumb for atypical haemolytic uraemic syndrome - RED Stribild® for the treatment of HIV infection - RED Plerixafor (Mozobil®) for Stem Cell Mobilisation - RED Rituximab (Mab Thera®) for Systemic Lupus Erythematosus - RED 	

	<p><u>PROCESS PROPOSALS</u></p> <p>No Process Proposals for consideration</p>	
	<p><u>GUIDELINES AND INFORMATION LEAFLETS</u></p>	
2013/139	<p><u>Rheumatology pathway – Cancer Flexes</u></p> <p>WL summarised the evidence review conducted for this proposed flex, and summarised the discussions from the previous LMMG meeting. The proposed flex was then discussed in the context of the Pan-Lancashire Policies and Principles for Commissioning.</p> <p>Following discussions, LMMG voted to accept the proposed flex that permits the use of rituximab as a first-line biologic in the treatment of rheumatoid arthritis patients who have a history of cancer in the last 5 years, or any history of malignant melanoma. Assurance was required that all patients would be provided with written information outlining the current evidence base for this use of rituximab in these circumstances.</p> <p><u>Action:</u> WL to contact the Alliance for assurance that patients are provided with written evidence outlining the current evidence base.</p>	<p>WL to contact the Alliance for assurance</p>
2013/141	<p><u>Infant feeding guidelines</u></p> <p>JLon presented the paper and reminded LMMG that in the July 2013 meeting it was recommended that the guidelines were reviewed with the Lancashire Infant Feeding Information Board (LIFIB) in view of the comments that had been received during the consultation process. Further work has been carried out as requested and the guidelines have been amended and were now presented for discussion.</p> <p>The committee felt that the summary in relation to soya products on page 2 should be amended to read “Soya products should not be recommended for purchase unless”</p> <p>The LIFIB were unable to state if pre-term discharge formula should be prescribed on discharge as they do not have decision making powers and could only provide the evidence base and their interpretation of the evidence base. Three options were therefore given for possible wording on the use of second stage formulas post discharge and LMMG discussed the best option for the guideline.</p> <p>It was agreed that the guideline should state the following “A Cochrane review has found no substantiation for the use of ‘post discharge’ formula, such as Nutriprem 2, over normal proprietary brand ‘first stage’ infant formulae. Therefore they are not recommended to be prescribed post discharge on the NHS in Lancashire.”</p> <p>LMMG queried if a consultant paediatrician had been involved in reviewing the guidelines via the LIFIB</p> <p><u>Action:</u> JLon to contact Lancashire Infant Feeding Board (LIFIB) for further clarification whether a consultant paediatrician was involved</p> <p>Following the amendments above and confirmation of paediatrician involvement LMMG recommended the guidelines to CCGs</p>	<p>JLon to contact LIFIB</p>
	<p><u>OTHER PROPOSALS</u></p> <p>None</p>	

2013/142	<p><u>Lancashire RAG list harmonisation</u></p> <p>LMMG decided this item was to be deferred to the next meeting 14th November 2013</p> <p>Action: JLon to add to the next agenda</p>	JLon
2013/143	<p><u>Vac & Imm PGDs on LMMG Website</u></p> <p>JLon raised the question of the vac & imm PGDs being hosted on the LMMG website and if agreed what format was most appropriate</p> <p>LMMG agreed the PGDs could be hosted on the website for Lancashire and agreed the preferred format would be a PDF of the PGD with signatures.</p> <p>The issue was raised whether all signatories would be happy to have their signature displayed on the website.</p> <p>Action: JLon to take back to the PGD group and check with signatories if they would be happy with the proposal. To investigate if it is possible to load the documents as read/print only so they can't be downloaded.</p>	JLon
2013/144	<p>Lancashire Care FT Drug & Therapeutic Committee Minutes 1st October</p> <p>The minutes of the Lancashire Care Drugs & Therapeutic Committee meeting will be considered at the November LMMG.</p>	

Date and time of the next meeting

Thursday 14th November 9.30 am to 11.30 am, Meeting Room 1 Preston Business Centre

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2013/131	<u>2013/117 Tapentadol SR – Item outstanding from last agenda for action</u> BH updated LMMG that the letter is now drafted but not yet sent to pain management	BH	18.10.2013
2013/140	<u>ADHD SHARED CARE DOCUMENT</u> TN to take for further discussion to the CAG To develop an information sheet to support GP's with assessments required	TN JLon / Sonia Ramdour	14.11.2013 14.11.2013
2013/133	<u>Ticagrelor</u> WL to contact the Cardiac Network for an agreed treatment protocol / algorithm	WL	17.10.2013
2013/134	<u>Lisdexamfetamine</u> BH to update the recommendation and upload to the website	BH	17.10.2013
2013/135	<u>Medicines Horizon Scanning Paper Quarter 3 2013/14</u> BH to add Ultibro® inhaler to the LMMG work plan	BH	17.10.2013
2013/139	<u>Rheumatology pathway – Cancer Flexes</u> WL to contact the Rheumatology Alliance for assurance that patients receive written information outlining the current evidence base in patients with a history of cancer	WL	17.10.13
2013/141	<u>Infant feeding guidelines</u> JLon to contact Lancashire Infant Feeding Information Board (LIFIB) for further clarification and if a paediatrician was involved in drafting / amending the guideline. JLon to amend the document in line with the changes agreed at LMMG.	JLon JLon	14.11.2013 17.10.13
2013/142	<u>Lancashire RAG list harmonisation</u> LMMG decided this item was to be deferred to the next meeting 14 th November 2013 JLon to add to the next agenda	JLon	14.11.2013

2013/143	<u>Vac & Imm PGDs on LMMG Website</u> JLon to take back to the PGD group and check with signatories if they would be happy with the proposal.	JLon	14.11.2013
-----------------	---	-------------	-------------------